CA2865351C - Thiadiazolidinediones as gsk-3 inhibitors - Google Patents
Thiadiazolidinediones as gsk-3 inhibitors Download PDFInfo
- Publication number
- CA2865351C CA2865351C CA2865351A CA2865351A CA2865351C CA 2865351 C CA2865351 C CA 2865351C CA 2865351 A CA2865351 A CA 2865351A CA 2865351 A CA2865351 A CA 2865351A CA 2865351 C CA2865351 C CA 2865351C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- solvate
- disease
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382066 | 2012-02-24 | ||
| EP12382066.4 | 2012-02-24 | ||
| PCT/EP2013/053554 WO2013124413A1 (en) | 2012-02-24 | 2013-02-22 | Thiadiazolidinediones as gsk-3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2865351A1 CA2865351A1 (en) | 2013-08-29 |
| CA2865351C true CA2865351C (en) | 2019-08-20 |
Family
ID=47747639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2865351A Active CA2865351C (en) | 2012-02-24 | 2013-02-22 | Thiadiazolidinediones as gsk-3 inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9371299B2 (https=) |
| EP (1) | EP2838888B1 (https=) |
| JP (2) | JP6073377B2 (https=) |
| AU (2) | AU2013224041B2 (https=) |
| CA (1) | CA2865351C (https=) |
| CY (1) | CY1119231T1 (https=) |
| DK (1) | DK2838888T3 (https=) |
| ES (1) | ES2632428T3 (https=) |
| HR (1) | HRP20170964T1 (https=) |
| HU (1) | HUE035089T2 (https=) |
| IN (1) | IN2014DN07885A (https=) |
| LT (1) | LT2838888T (https=) |
| NZ (1) | NZ630615A (https=) |
| PL (1) | PL2838888T3 (https=) |
| PT (1) | PT2838888T (https=) |
| SI (1) | SI2838888T1 (https=) |
| WO (1) | WO2013124413A1 (https=) |
| ZA (1) | ZA201406225B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2632428T3 (es) | 2012-02-24 | 2017-09-13 | Asd Therapeutics Partners Llc | Nuevas tiadiazolidinadionas como inhibidores de GSK-3 |
| LT2970890T (lt) | 2013-03-14 | 2020-07-10 | The Brigham And Women`S Hospital, Inc. | Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui |
| CN106794175B (zh) * | 2014-06-12 | 2020-06-09 | 西达-赛奈医疗中心 | 用于治疗癌症的组合物 |
| WO2016037016A1 (en) | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| CN108779437A (zh) | 2016-01-08 | 2018-11-09 | 麻省理工学院 | 分化的肠内分泌细胞和胰岛素产生细胞的制备 |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US11066419B2 (en) | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| CN113195707A (zh) | 2018-08-17 | 2021-07-30 | 频率治疗公司 | 用于通过上调jag-1来生成毛细胞的组合物和方法 |
| MX2021004341A (es) * | 2018-10-16 | 2021-08-19 | Italia Tech Alliance S R L | Bobinadora con un sistema de evaluacion del material de entramado que se procesa y metodo. |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| JP2024508732A (ja) * | 2021-02-11 | 2024-02-28 | ベンカ リサーチ，インコーポレイティド | 不整脈原性心筋症を治療するための組成物および方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02011079A (es) | 2000-05-11 | 2004-08-19 | Consejo Superior Investigacion | Inhibidores heterociclicos de quinasa de sintasa de glucogeno gsk3. |
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| EP1586318A1 (en) | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| KR100837785B1 (ko) * | 2007-01-17 | 2008-06-13 | 한국화학연구원 | 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물 |
| ES2632428T3 (es) | 2012-02-24 | 2017-09-13 | Asd Therapeutics Partners Llc | Nuevas tiadiazolidinadionas como inhibidores de GSK-3 |
-
2013
- 2013-02-22 ES ES13705492.0T patent/ES2632428T3/es active Active
- 2013-02-22 SI SI201330704T patent/SI2838888T1/sl unknown
- 2013-02-22 WO PCT/EP2013/053554 patent/WO2013124413A1/en not_active Ceased
- 2013-02-22 EP EP13705492.0A patent/EP2838888B1/en active Active
- 2013-02-22 HU HUE13705492A patent/HUE035089T2/hu unknown
- 2013-02-22 PL PL13705492T patent/PL2838888T3/pl unknown
- 2013-02-22 PT PT137054920T patent/PT2838888T/pt unknown
- 2013-02-22 DK DK13705492.0T patent/DK2838888T3/en active
- 2013-02-22 CA CA2865351A patent/CA2865351C/en active Active
- 2013-02-22 LT LTEP13705492.0T patent/LT2838888T/lt unknown
- 2013-02-22 US US14/380,623 patent/US9371299B2/en active Active
- 2013-02-22 AU AU2013224041A patent/AU2013224041B2/en active Active
- 2013-02-22 IN IN7885DEN2014 patent/IN2014DN07885A/en unknown
- 2013-02-22 NZ NZ630615A patent/NZ630615A/en unknown
- 2013-02-22 JP JP2014558118A patent/JP6073377B2/ja active Active
- 2013-02-22 HR HRP20170964TT patent/HRP20170964T1/hr unknown
-
2014
- 2014-08-25 ZA ZA2014/06225A patent/ZA201406225B/en unknown
-
2016
- 2016-05-16 US US15/155,437 patent/US9469618B2/en active Active
-
2017
- 2017-01-04 JP JP2017000211A patent/JP6518270B2/ja active Active
- 2017-07-12 CY CY20171100737T patent/CY1119231T1/el unknown
- 2017-10-20 AU AU2017248556A patent/AU2017248556B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017081974A (ja) | 2017-05-18 |
| PL2838888T3 (pl) | 2017-12-29 |
| IN2014DN07885A (https=) | 2015-04-24 |
| US20150038538A1 (en) | 2015-02-05 |
| SI2838888T1 (sl) | 2017-09-29 |
| EP2838888A1 (en) | 2015-02-25 |
| US20160257660A1 (en) | 2016-09-08 |
| LT2838888T (lt) | 2017-08-10 |
| JP6073377B2 (ja) | 2017-02-01 |
| HUE035089T2 (hu) | 2018-05-02 |
| PT2838888T (pt) | 2017-07-18 |
| AU2013224041B2 (en) | 2017-08-24 |
| HK1207366A1 (en) | 2016-01-29 |
| JP6518270B2 (ja) | 2019-05-22 |
| JP2015508092A (ja) | 2015-03-16 |
| US9469618B2 (en) | 2016-10-18 |
| CA2865351A1 (en) | 2013-08-29 |
| ES2632428T3 (es) | 2017-09-13 |
| EP2838888B1 (en) | 2017-04-12 |
| WO2013124413A1 (en) | 2013-08-29 |
| NZ630615A (en) | 2015-09-25 |
| AU2017248556B2 (en) | 2018-08-09 |
| AU2013224041A1 (en) | 2014-09-25 |
| DK2838888T3 (en) | 2017-07-17 |
| US9371299B2 (en) | 2016-06-21 |
| CY1119231T1 (el) | 2018-02-14 |
| HRP20170964T1 (hr) | 2017-10-06 |
| ZA201406225B (en) | 2016-05-25 |
| AU2017248556A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2865351C (en) | Thiadiazolidinediones as gsk-3 inhibitors | |
| TWI352084B (en) | Gsk-3 inhibitors | |
| AU2007245625B2 (en) | N- ( 2-thiazolyl) -amide derivatives as GSK-3 inhibitors | |
| KR101471999B1 (ko) | Ｇｓｋ-3 저해제 | |
| US20050054698A1 (en) | 4-(4Methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3) | |
| HK1207366B (en) | Thiadiazolidinediones as gsk-3 inhibitors | |
| WO2013149976A1 (en) | Indole-pyrimidine derivatives and their therapeutic uses | |
| EP2527322A1 (en) | Carbamyl alkylphenyl disulfide derivatives and their therapeutic uses | |
| EP2527323A1 (en) | Urea carbonyl disulfide derivatives and their therapeutic uses | |
| WO2013167635A1 (en) | Therapeutic use of indole-dihydro-imidazole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170814 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250214 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250214 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250214 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260216 |